Search research articles
Contact Us
Filters
Showing results (11-20 of 99) with videos related to
Page
of 10
Sort By:
Journal of Neuro-Oncology
|
August 8, 2002
Docetaxel-induced nail changes--a neurogenic mechanism: a case report
Gunnar Wasner, Felix Hilpert, Jörn Schattschneider, et al.
Journal of Analytical Toxicology
|
May 21, 2005
Simultaneous congener-specific determination of selected organochlorine compounds and nitro musks in human whole blood samples by solid-phase extraction and capillary gas chromatography with electron capture detection
Maret Bauer, Felix Hilpert, Norbert Arnold, et al.
Expert Review of Anticancer Therapy
|
December 18, 2009
Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
Philipp Harter, Felix Hilpert, Sven Mahner, et al.
Gynecologic Oncology
|
March 7, 2006
Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol)
Stefan Kommoss, Andreas du Bois, Dietmar Schmidt, et al.
Gynecologic Oncology
|
March 26, 2005
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel
Friedrich Kommoss, Stefan Kommoss, Dietmar Schmidt, et al.
Human Immunology
|
September 29, 2009
Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment
Silke Reinartz, Jacobus Pfisterer, Andreas du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 4, 2009
Prognostic factors for complete debulking in first- and second-line ovarian cancer
Philipp Harter, Felix Hilpert, Sven Mahner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials
Andreas du Bois, Alexander Reuss, Philipp Harter, et al.
Expert Opinion on Biological Therapy
|
January 19, 2011
Abagovomab for ovarian cancer
Jacobus Pfisterer, Philipp Harter, Cecilia Simonelli, et al.
Cancer
|
February 4, 2009
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Page
of 10
Search research articles
Search
Showing results (11-20 of 99) with videos related to
Sort By:
Page
of 10
Journal of Neuro-Oncology
|
August 8, 2002
Docetaxel-induced nail changes--a neurogenic mechanism: a case report
Gunnar Wasner, Felix Hilpert, Jörn Schattschneider, et al.
Journal of Analytical Toxicology
|
May 21, 2005
Simultaneous congener-specific determination of selected organochlorine compounds and nitro musks in human whole blood samples by solid-phase extraction and capillary gas chromatography with electron capture detection
Maret Bauer, Felix Hilpert, Norbert Arnold, et al.
Expert Review of Anticancer Therapy
|
December 18, 2009
Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
Philipp Harter, Felix Hilpert, Sven Mahner, et al.
Gynecologic Oncology
|
March 7, 2006
Chemotherapy may be more effective in highly proliferative ovarian carcinomas--a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol)
Stefan Kommoss, Andreas du Bois, Dietmar Schmidt, et al.
Gynecologic Oncology
|
March 26, 2005
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel
Friedrich Kommoss, Stefan Kommoss, Dietmar Schmidt, et al.
Human Immunology
|
September 29, 2009
Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment
Silke Reinartz, Jacobus Pfisterer, Andreas du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 4, 2009
Prognostic factors for complete debulking in first- and second-line ovarian cancer
Philipp Harter, Felix Hilpert, Sven Mahner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2010
Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials
Andreas du Bois, Alexander Reuss, Philipp Harter, et al.
Expert Opinion on Biological Therapy
|
January 19, 2011
Abagovomab for ovarian cancer
Jacobus Pfisterer, Philipp Harter, Cecilia Simonelli, et al.
Cancer
|
February 4, 2009
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)
Andreas du Bois, Alexander Reuss, Eric Pujade-Lauraine, et al.
Page
of 10